Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma

ClinicalTrials.gov ID: NCT04382664

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT04382664. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 4:48 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Efficacy and Safety of UV1 Vaccination in Combination With Nivolumab and Ipilimumab as First Line Treatment of Patients With Unresectable or Metastatic Melanoma (INITIUM Study)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a randomized, open label study to investigate efficacy and safety of UV1 vaccination in combination with nivolumab and ipilimumab as first line treatment of adult patients with histologically confirmed unresectable metastatic melanoma.

Study identification

NCT ID
NCT04382664
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Ultimovacs ASA
Industry
Enrollment
156 participants

Conditions and interventions

Interventions

Biological

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 27, 2020 (Actual)
Primary completion
Jan 11, 2024 (Actual)
Completion
Apr 10, 2024 (Actual)
Last update posted
Jan 14, 2025

2020 – 2024

United States locations

U.S. sites
20
U.S. states
11
U.S. cities
19
Facility City State ZIP Site status
Mayo Clinic Hospital Phoenix Arizona 85016-4880 —
Highlands Oncology Group Fayetteville Arkansas 72703 —
University of California Irvine Health Orange California 92868 —
California Cancer Associates for Research & Excellence (CCARE San Marcos California 92083 —
Ridley-Tree Cancer Center Santa Barbara California 93105 —
Saint John's Health Center - John Wayne Cancer Institute (JWCI) Santa Monica California 90404 —
University of Colorado Hospital - Anschutz Cancer Pavilion Aurora Colorado 80045 —
Holy Cross Medical Group Fort Lauderdale Florida 33308 —
Sylvester Comprehensive Cancer Center Miami Florida 33136-1002 —
Ocala Oncology Center Ocala Florida 34474 —
Rush University Medical Center - Rush University Cancer Center Chicago Illinois 60612-3841 —
NorthShore University Research Institute Evanston Illinois 60201-1718 —
Oncology Specialists, S.C. Park Ridge Illinois 60068 —
Norton Cancer Institute Louisville Kentucky 40241 —
Nebraska Cancer Specialists- Midwest Cancer Center Papillion Nebraska 68046-5706 —
Icahn School of Medicine at Mount Sinai New York New York 10029 —
State University of New York (SUNY) Upstate Medical University New York New York 13210 —
University of Rochester Rochester New York 14642-0001 —
NorthShore University HealthSystem Greenville South Carolina 29607 —
Texas Oncology - Baylor Charles A. Sammons Cancer Center Dallas Texas 75246-2092 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 17 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04382664, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 14, 2025 · Synced Nov 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.